Roche's world's first accelerator launched in Shanghai

On May 18, Roche China Accelerator was officially launched in Shanghai Zhangjiang High-tech Roche Park
.
At the launching ceremony, Roche signed strategic cooperation agreements with Hillhouse Ventures and Zhangjiang Group

Increase R&D investment in China to empower medical industry innovation

With an investment of more than 200 million yuan, Roche China Accelerator will integrate Roche's own resources and advantages, and provide personalized support plans for start-ups in the fields of innovative drugs, diagnosis, personalized medicine, and artificial intelligence through agile and flexible cooperation methods
.
The settled start-ups can obtain Roche's full-chain localized resource support from early R&D to late commercialization, including scientific and technical guidance, business strategy guidance, and operational support

The new Roche Accelerator Building will be completed and put into use in the first quarter of 2022.
It is located in Zhangjiang High-tech Park in Pudong New Area, covering an area of ​​more than 5,000 square meters
.
In the future, Roche Shanghai Innovation Center and Roche Group’s global R&D scientists will actively participate in and share, provide entrepreneurs with high-quality laboratories and offices, and establish cooperation on the basis of voluntary complementarity between the two parties, and through accelerators, they will nurture a number of global occupations.

At the launching ceremony, Roche Group CEO Dr.
Shi Wan and Roche’s global drug research and early development head Dr.
William Pao expressed their confidence in the Chinese market and expectations of accelerators through online participation
.
Dr.

Dr.

From global introduction to local incubation, promoting Chinese R&D to the world

The Roche Group has a history of more than 90 years with China, and has always fulfilled its long-term commitment to China and is committed to providing Chinese patients with first-class differentiated medicines and diagnostic solutions

Today's Roche China Accelerator is another strategic innovation initiative of Roche following the completion of the Roche Shanghai Innovation Center in 2019
.
Roche has joined hands with strategic partners, including Zhangjiang Group, Hillhouse Ventures, etc.

As an important partner of the accelerator, Zhangjiang Group will provide strong support for the establishment and operation of Roche China Accelerator, Hillhouse Ventures will selectively provide capital support for high-quality start-up companies and projects, and jointly promote the innovation of China's biomedical industry Development

"Roche is the first multinational pharmaceutical company to settle in Zhangjiang, Shanghai.
It has been rooted in China for 27 years.
We have witnessed too many firsts in this land
.
" said Ms.
Zhou Hong, President of Roche Pharmaceuticals China.

National boundaries .
The launch of Roche China Accelerator marks an important transition from introducing global innovations to incubating local innovations.
Roche is committed to building China into a global innovation center
.
Adhering to the concept of "walking for patients first", we will continue to do so in the future Work with our partners to build a healthcare ecosystem, promote Chinese R&D to the world, and accelerate the benefit of patients in China and the world
.
"

       "As a pioneer in the field of in vitro diagnostics, Roche Diagnostics has always been open to cooperation with local start-ups to empower the construction of China's innovation ecosystem
.
Relying on our R&D and commercial strength in the Chinese market, we hope to provide strong support to local companies
.
"Roche Diagnostics China General Manager Yao Guoliang said, "In vitro diagnostics plays an important role in all stages of disease management
.
With the help of the Roche China Accelerator Project, we are committed to cooperating with local governments and industry partners to research and discover more advanced whole Solutions to promote the development of personalized medicine, so as to bring more well-being to patients
.
"